References
- Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Anti-Tumour Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group: Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III study. Lancet 1999; 354: 1932–9
- Crum NF, Lederman ER, Wallace MR. Infections associated with tumour necrosis factor-α antagonists. Medicine 2005; 84: 291–302
- Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumour necrosis factor antagonists. Clin Infect Dis 2004; 38: 1261–5
- Wallis RS, Broder M, Wong J, Lee A, Hoq L. Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis 2005; 41: S194–8
- Pegues DA, Ohl ME, Miller SI. Principles and Practice of Infectious Diseases, Chapter 220. Salmonellae, GL Mandell, JE Bennett, R Dolin. Elsevier, Churchill Livingstone. 2004; 2636–54
- Hohmann EL. Non-typhoidal salmonellosis. Clin Infect Dis 2001; 32: 263–9
- Mastroeni P, Harrison JA, Robinson JH, Clare S, Khan S, Maskell DJ, et al. Interleukin-12 is required for control of the growth of attenuated aromatic-compound- dependent Salmonellae in BALB/c mice: role of gamma-interferon and macrophage activation. Infect Immun 1998; 66: 4767–76
- Everest P, Roberts M, Dougan G. Susceptibility to Salmonella typhimurium infection and effectiveness of vaccination in mice deficient in the tumour necrosis necrosis factor alpha p55 receptor. Infect Immun 1998; 66: 3355–64
- Hess J, Ladel C, Miko D, Kaufmann SH. Salmonella typhimurium aroA-infection in gene-targeted immunodeficient mice: major role of CD4+ TCR-alpha beta cells and IFN-gamma in bacterial clearance independent of intracellular location. J Immun 1996; 156: 3321–6
- Jouanguy E, Doffinger R, Dupuis S, Pallier A, Altare F, Casanova JL. IL-12 and IFN-gamma in host defence against mycobacteria and Salmonella in mice and men. Curr Opin Immunol 1999; 11: 346–51
- Netea MG, Radstake T, Joosten LA, van der Meer JWM, Barrera P, Kullberg BJ. Salmonella septicaemia in rheumatoid arthritis patients receiving anti-tumour necrosis factor therapy. Arthritis Rheum 2003; 48: 1853–7
- Fu A, Bertouch JV, McNeil HP. Disseminated Salmonella typhimurium infection secondary to infliximab treatment. Arthritis Rheum 2004; 50: 3049–60
- Popa C, Netea MG, Barrera P, Radstake TRDS, Riel PL, Kullberg BJ, van der Meer JWM. Cytokine production of stimulated whole blood cultures in rheumatoid arthritis patients receiving short-term infliximab therapy. Cytokine 2005; 30: 72–7
- Hess DJ, Henry-Stanley MJ, Erickson EA, Wells CL. Effect of tumour necrosis factor α, interferon γ, and interleukin-4 on bacteria-enterocyte interactions. J Surg Research 2002; 104: 88–94
- Mastroeni P, Skepper JN, Hormaeche CE. Effect of anti-tumour necrosis factor alpha antibodies on histopathology of primary salmonella infections. Infect and Immun 1995:3674–82.